Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
RESEARCH TOOLSreports
Holding IKT?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.09Last Year’s EPS
-$0.64Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: 32.23%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.Company Guidance
During the Inhibikase Therapeutics Q2 2024 earnings call, executives highlighted several key metrics and developments. The company completed enrollment for the Phase II trial of risvodetinib in Parkinson's disease, expecting to report top-line data in November. They observed 49 adverse events and had six withdrawals from the trial. For their IkT-001Pro, a prodrug formulation aimed at pulmonary arterial hypertension (PAH), they filed an IND on August 9, 2024, with plans for a Phase IIb trial involving around 100 patients. Financially, Inhibikase reported a net loss of $5.0 million for the quarter, with R&D expenses decreasing by $1.5 million to $3.1 million, and a cash position of $7.9 million as of June 30, 2024. The company expects its cash runway to extend into December 2024, bolstered by raising $4 million in May from registered direct offering and concurrent private placement.Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.
Progress with IkT-001Pro for PAH
The company filed the IND for IkT-001Pro targeting pulmonary arterial hypertension (PAH) and plans to initiate a Phase IIb study. The market value for PAH treatments is estimated at $7.7 billion annually.
Financial Strength
Inhibikase raised $4 million from a registered direct offering and concurrent private placement, extending their cash runway into December 2024.
Decrease in Net Loss
Net loss for Q2 2024 was $5.0 million, or $0.66 per share, compared to $5.8 million, or $0.94 per share, for Q2 2023, indicating improved financial management.
---
IKT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IKT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $2.42 | $2.36 | -2.48% |
| Aug 14, 2024 | $1.30 | $1.23 | -5.38% |
| May 16, 2024 | $1.99 | $1.76 | -11.56% |
| Mar 27, 2024 | $2.30 | $2.16 | -6.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inhibikase Therapeutics (IKT) report earnings?
Inhibikase Therapeutics (IKT) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Inhibikase Therapeutics (IKT) earnings time?
Inhibikase Therapeutics (IKT) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IKT EPS forecast?
IKT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.09.
---